HC Wainwright Reaffirms “Neutral” Rating for Shattuck Labs (NASDAQ:STTK)

Shattuck Labs (NASDAQ:STTK)‘s stock had its “neutral” rating restated by equities researchers at HC Wainwright in a research note issued on Thursday,Benzinga reports.

Several other equities analysts also recently weighed in on the company. Leerink Partners started coverage on Shattuck Labs in a report on Monday, March 17th. They set an “outperform” rating and a $4.00 price target for the company. Leerink Partnrs raised shares of Shattuck Labs to a “strong-buy” rating in a report on Monday, March 17th. Four analysts have rated the stock with a hold rating, one has assigned a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, Shattuck Labs presently has an average rating of “Moderate Buy” and an average target price of $7.50.

Shattuck Labs Stock Down 7.5 %

Shares of NASDAQ STTK opened at $1.06 on Thursday. The firm has a market capitalization of $50.37 million, a P/E ratio of -0.69 and a beta of 1.66. Shattuck Labs has a twelve month low of $0.94 and a twelve month high of $11.76. The stock’s 50-day simple moving average is $1.24 and its two-hundred day simple moving average is $1.49.

Shattuck Labs (NASDAQ:STTK) last released its quarterly earnings results on Thursday, March 27th. The company reported ($0.37) EPS for the quarter, beating analysts’ consensus estimates of ($0.38) by $0.01. Shattuck Labs had a negative return on equity of 61.92% and a negative net margin of 1,156.46%. As a group, research analysts anticipate that Shattuck Labs will post -1.48 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Connor Clark & Lunn Investment Management Ltd. increased its position in shares of Shattuck Labs by 44.1% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 178,228 shares of the company’s stock valued at $622,000 after purchasing an additional 54,505 shares during the last quarter. FMR LLC raised its stake in shares of Shattuck Labs by 0.4% in the third quarter. FMR LLC now owns 7,159,090 shares of the company’s stock valued at $24,985,000 after acquiring an additional 26,460 shares during the period. MetLife Investment Management LLC boosted its stake in shares of Shattuck Labs by 129.1% during the 3rd quarter. MetLife Investment Management LLC now owns 24,596 shares of the company’s stock worth $86,000 after purchasing an additional 13,859 shares during the period. Atom Investors LP bought a new position in Shattuck Labs during the 3rd quarter valued at about $35,000. Finally, Benjamin Edwards Inc. purchased a new stake in Shattuck Labs in the 3rd quarter worth about $61,000. Institutional investors own 58.74% of the company’s stock.

Shattuck Labs Company Profile

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.